MedTrace Logo

Uterine Cavity and Blood Flow After Conservative Management of Placenta Previa/Accreta

NCT02878187 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-05-13

No results posted yet for this study

Summary

Bleeding is the most significant cause of maternal death worldwide with more than half of those occurring within the first day of delivery. About 10.5% (some estimate as high at 12-17%) of live births world-wide, or about 14 million births, are complicated by postpartum hemorrhage; a woman dies every 4 minutes from postpartum hemorrhage. Uterine atony and placenta accreta are the two leading causes of postpartum hysterectomies with up to 64% of Cesarean hysterectomies done for abnormally adherent placentation

Conditions

  • Improving Quality of Life

Interventions

DEVICE

Doppler

Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated: The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahmed Abbas, MD · Assiut University

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-15
Primary Completion
2019-12-31
Completion
2020-05-31

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878187 on ClinicalTrials.gov